![](https://signpathpharma.com/wp-content/uploads/2018/01/Pipeline-Image-1.png)
![](https://signpathpharma.com/wp-content/uploads/2018/01/Pipeline-Image-2.png)
![](https://signpathpharma.com/wp-content/uploads/2018/01/Pipeline-Image-3.png)
![](https://signpathpharma.com/wp-content/uploads/2018/01/Pipeline-Image-4.png)
In addition to our clinical stage program in LipoCurc™ for the treatment of cancer, we are developing our CorreQT technology for treatment of cardiac arrhythmia, and the mitigation of cardiomyopathy associated with chemotherapy.
![](https://signpathpharma.com/wp-content/uploads/2018/02/Pipeline-Charts3.png)
LV Rate of Contraction
In animal studies, guinea pigs who were administered chemotherapy showed significantly greater heart function when the chemotherapy was co-administered with Signpath’s CorreQT adjuvant.
CorreQT technology protects the heart from damage caused by chemotherapy
Protecting the Heart from Damage During Chemotherapy
Using the CorreQT technology platform, Signpath is developing a drug which protects the heart from damage caused by administration of chemotherapy agents. Pre-clinical data shows that Signpath compounds are effective in mitigating the heart muscle damage which is a common side effect of cancer chemotherapy. In addition, testing confirms that Signpath’s compound does not interfere with the anti-cancer efficacy of the chemotherapy agent. Signpath is working on compound optimization for this cancer supportive care indication. The goal is to create a cardio-protective agent that is widely used in conjunction with a broad spectrum of chemotherapy agents (a cancer adjuvant model similar to Amgen’s Neupogen.) The cancer supportive care drug market was $22.9 billion in 2015.